March 2024 Annals highlights
This month’s articles and reviews provide guidance for these changes in our treatment pathways.
AllergyTalk podcast features OUtMATCH study
The FDA announced its approval of omalizumab as the first biologic medication to treat patients with food allergy.
It takes a village
What does it take to bring the ACAAI Annual Scientific Meeting to life each year? Believe it or not, planning takes years to prepare.
2024 Cyberattacks cause disruptions
Due to the attack, Change Healthcare's systems are still down, causing struggles for physician practices and hospitals filing claims, as well as for pharmacies…
AllergyTalk: Two Special Podcasts: Omalizumab for Food Allergy
On February 16, 2024, the FDA announced the approval of the first biologic medication to treat patients with food allergy, omalizumab
Clinical Trial Resources provide an important link to medical research
Learn about opportunities that may help your patients either now or in the future.
Addressing Cannabis use with patients
A survey revealed 75% of surveyed allergists were only somewhat knowledgeable about respiratory effects and allergic reactions to cannabis
Coding for E&M visit and allergy testing on the same day
Many third-party payers insist skin tests are a part of an office visit, but this is not the case, and these denials should be appealed.
Impact of 340B Drug Discount Program
While 340B is not the most relevant federal program for allergy practices, it is helpful to have a better understanding of how it works.